ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2020

Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system.

Tsung-Ying Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.